文献速递产科

硝苯地平用于早产急性宫缩抑制:安慰剂对照随机试验

Nifedipine for Acute Tocolysis of Preterm Labor: A Placebo-Controlled Randomized Trial.
PubMed 文献 · Obstet Gynecol · 2021-01-01

该随机双盲安慰剂对照试验纳入90例28 0/7至33 6/7周单胎早产临产孕妇,比较口服硝苯地平与安慰剂抑制宫缩的效果。因中期分析无效提前终止,最终分析88例。硝苯地平组与安慰剂组37周前分娩率(52% vs 48%,RR 1.1,95%CI 0.7-1.7)及48小时内分娩率均无显著差异,新生儿结局亦无差异。

要点

  • 硝苯地平急性宫缩抑制未降低37周前分娩率(52% vs 48%,RR 1.1)。
  • 硝苯地平未提高48小时内分娩阻断率(78% vs 71%,RR 1.1)。
  • 因中期分析显示无效,试验提前终止,样本量小于原计划。

核心结论

  • 硝苯地平急性宫缩抑制未影响早产率、48小时内分娩率或新生儿结局。

研究设计与样本

  • 随机双盲安慰剂对照试验,纳入28 0/7至33 6/7周单胎早产临产孕妇,计划150例,因无效提前终止,最终分析88例(硝苯地平组46例,安慰剂组42例)。

主要发现

  • 37周前分娩率硝苯地平组52% vs 安慰剂组48%,RR 1.1,95%CI 0.7-1.7,无显著差异。
  • 随机化后至少48小时分娩率硝苯地平组78% vs 安慰剂组71%,RR 1.1,95%CI 0.9-1.4,无显著差异。
  • 两组新生儿结局无显著差异。

关键数值与推荐

  • 硝苯地平用法:口服20 mg,90分钟后若宫缩持续重复一次,此后每4小时一次完成48小时方案。

临床怎么用

  • 不推荐将硝苯地平用于早产急性宫缩抑制以预防早产。

局限性

  • 试验因无效提前终止,实际样本量88例低于计划150例。
  • 仅纳入28 0/7至33 6/7周、宫口扩张2至4 cm的单胎孕妇,结论外推受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the effectiveness of acute nifedipine tocolysis in preventing preterm birth in women in preterm labor. METHOD: This was a randomized, double-blind, placebo-controlled trial of nifedipine in women with a singleton pregnancy between 28 0/7 and 33 6/7 weeks of gestation who were admitted with uterine activity, intact membranes, and cervical dilatation from 2 to 4 cm. Women were randomized to receive nifedipine 20 mg or placebo orally, followed by a repeat dose after 90 minutes if contractions persisted. The study drug was continued every 4 hours to complete a 48-hour regimen. The primary outcome was birth before 37 weeks of gestation. A total of 150 women were necessary to detect a one-third reduction in this outcome. After treating 88 patients, a preplanned interim analysis of blinded outcomes by the Data Safety Monitoring Committee recommended discontinuation of the trial due to futility. RESULTS: A total of 90 women were enrolled between May 2014 and November 2017. After two women withdrew, 88 were analyzed: 46 in the nifedipine group and 42 in the placebo group. There was no significant difference in the primary outcome of delivery before 37 weeks of gestation in the nifedipine group compared with the placebo group (52% vs 48%, relative risk [RR] 1.1, 95% CI 0.7-1.7), nor in the secondary outcome of delivery at least 48 hours from randomization (78% vs 71%, respectively, RR 1.1, 95% CI 0.9-1.4). There were also no significant differences between groups in neonatal outcomes. CONCLUSION: Acute tocolysis of preterm labor with nifedipine did not affect preterm birth rates, delivery within 48 hours, or neonatal outcomes. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT02132533.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Hawkins JS, Wells CE, Casey BM, et al. Nifedipine for Acute Tocolysis of Preterm Labor: A Placebo-Controlled Randomized Trial. Obstet Gynecol. 2021. PMID: 34259466. doi:10.1097/AOG.0000000000004436

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。